# Improved Treatment and Monitoring of Alzheimer's Disease

> **NCT07135245** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Rune Skovgaard Rasmussen** · enrollment: 180 (estimated)

## Conditions studied

- Alzheimer Disease (AD)

## Interventions

- **DRUG:** Semaglutide (Rybelsus®) combined with other interventions
- **OTHER:** Placebo
- **DRUG:** Semaglutide (Rybelsus®)

## Key facts

- **NCT ID:** NCT07135245
- **Lead sponsor:** Rune Skovgaard Rasmussen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2030-09-30
- **Final completion:** 2031-09-30
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2025-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07135245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07135245, "Improved Treatment and Monitoring of Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07135245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*